Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

TScan Therapeutics (TCRX) Accumulated Depreciation & Amortization (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 29.27% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 29.27% year-over-year, with the annual reading at $2.9 million for FY2025, 29.27% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $2.9 million at TScan Therapeutics, down from $4.1 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $5.4 million in Q4 2023, with the low at $2.9 million in Q4 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $4.2 million, with a median of $4.1 million recorded in 2024.
  • The sharpest move saw Accumulated Depreciation & Amortization soared 175.0% in 2021, then dropped 29.27% in 2025.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $3.3 million in 2021, then soared by 54.55% to $5.1 million in 2022, then rose by 5.88% to $5.4 million in 2023, then fell by 24.07% to $4.1 million in 2024, then fell by 29.27% to $2.9 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $2.9 million, $4.1 million, and $5.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.